GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Indaptus Therapeutics INDP · USD

Health Care · US listing · 🇺🇸 United States

Compare

3.13

-5.72%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Indaptus Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Indaptus Therapeutics is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker INDP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $20.8m. At that date it held total assets of $9.3m and shareholders' equity of $3.2m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
7 Sept 2012
Employees
6
Head office
3 COLUMBUS CIRCLE, NEW YORK, NY, 10019
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. Roger PomerantzIndependent Non-Executive Chairman of the Board$216,000
  • Mr. Jeffrey MecklerChief Executive Officer, Director, since 2021$1.2m
  • Mr. Nir SassiChief Financial Officer, Treasurer, Secretary$600,848
  • Mr. Walt LinscottChief Operating Officer$970,400
  • Dr. Michael NewmanChief Scientific Officer, Director, since 2021$718,039
  • Dr. Roger WaltzmanChief Medical Officer$928,879
  • Dr. Mark GilbertIndependent Director$81,500
  • Mr. William HayesIndependent Director$98,500
  • Ms. Hila KarahIndependent Director$93,000
  • Mr. Anthony MaddalunaIndependent Director$96,500
  • Dr. Robert MartellIndependent Director$89,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Pre-clinical biotechnology company with a focused approach on curative cancer immunotherapy.
  • Headquartered in New York City with a small team of six full-time employees.
  • Lead candidate Decoy20 is in pre-clinical development stage.

Weaknesses

  • Limited employee count of six full-time staff indicates potential resource constraints.
  • Company is pre-clinical with no clinical-stage products yet.
  • IPO occurred in 2012, suggesting a long development timeline without commercial products.

Opportunities

  • Expanding curative cancer immunotherapy for unresectable or metastatic solid tumors and lymphomas.
  • Targeting specific tumor or viral antigens could lead to novel therapeutic approaches.
  • Platform based on activating both innate and adaptive cellular immunity may offer unique advantages.

Threats

  • Pre-clinical stage with no approved products poses significant development risk.
  • Long development timeline since IPO in 2012 without commercialization.
  • Dependence on a single lead candidate, Decoy20, for future success.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.